8 results about "Pyridine sulfonamide" patented technology

The utility model discloses a processing reaction kettle for trifluoropyridine sulfonamide. The processing reaction kettle comprises a kettle body, a pressure release valve head and a feeding valve head are mounted on the upper end surface of a top carrier plate of the kettle body; an external member is synchronously mounted on the outer ring of the middle section of the kettle body, and frame-mounted driving mechanisms are mounted on the two sides of the external member; a mixed material output barrel is mounted in the center of the bottom of the kettle body, the bottom of the mixed material output barrel is in feeding connection with a material mixing barrel through an extension barrel, the material mixing barrel is of a transverse structure, and a feeding valve port is mounted at the end of the right side of the material mixing barrel. The utility model relates to a processing reaction kettle for trifluoropyridine sulfonamide, which adopts a suspension type reaction kettle structure, and is matched with a servo motor to drive to complete overturning at a local angle or complete a sequential 360-degree overturning framework, so that a material mixing processing procedure can be fully completed. The mixing barrel structure transversely mounted at the bottom can temporarily preset mixing raw materials to be reacted and processed, so that the effect of preset reaction or pretreatment is achieved. Meanwhile, the telescopic sleeve structure of the lifting structure can also increase the reaction volume.

The present disclosure relates to crystalline polymorphs of the compound of Formula (I), namely N-(4-bromo-2,5-difluorophenyl)-6-chloro-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide: [Refer to original abst

This invention relates to the field of organometallic complex catalysis, specifically disclosing an organometallic iridium complex capable of efficiently and selectively catalyzing the regeneration of coenzyme NADH and its preparation method. The organometallic iridium complex is a novel pentamethylcyclopentadienyl (Cp*)pyridinesulfonamide iridium complex. The advantage of this invention is that this organometallic iridium complex can efficiently and selectively catalyze the oxidation of coenzyme NAD. + Low-temperature hydrogenation converts it into reduced coenzyme NADH, and it exhibits good biocompatibility.

Use of a pyridine sulfonamide phosphate compound or a pharmaceutical composition comprising the same in the preparation of a drug for treating pulmonary edema. This drug inhibits the NKCC1 target in the lungs through a novel mechanism of action, demonstrating outstanding efficacy in treating pulmonary edema with high safety. It can significantly reduce drug distribution in kidney tissue, thereby reducing adverse effects such as electrolyte disturbances caused by potent diuretics. It holds promise as a novel drug for the clinical treatment of pulmonary edema and has a very broad clinical application prospect.

The invention relates to the technical field of chemical pharmaceutical synthesis, and particularly discloses a synthetic method of omipag isopropyl ester, and the synthetic method provided by the invention comprises three experimental steps of preparing a pyridine sulfonamide intermediate, preparing a bromo omipag isopropyl ester precursor and preparing omipag isopropyl ester. According to the present invention, the bromo-omipag isopropyl ester precursor is creatively constructed, and the bromo-omipag isopropyl ester precursor and the 2-amino acetic acid isopropyl ester hydrochloride are subjected to the Buchwald coupling reaction to synthesize the omipag isopropyl ester through the carbon-nitrogen coupling method; the synthesis of an unstable precursor is successfully avoided, so that the raw materials are easier to obtain, and the method has a good commercial application prospect.

A nasal spray composition for treating cerebral edema comprises a pyridine sulfonamide phosphate compound represented by formula 1 or a pharmaceutically acceptable salt thereof. The nasal spray of the present application has the advantages of high brain penetration, strong efficacy, few side effects, good patient compliance, convenient carrying and use, etc., significantly improving the effectiveness and safety of the drug. In addition, the nasal spray composition of the present application also contains a stabilizer, rhamnose. As a stabilizer, rhamnose can greatly improve the stability of the nasal spray composition.

The application provides a pyridine-3-sulfonamide compound and an application thereof. The pyridine-3-sulfonamide compound provided by the application is a novel structure inhibitor of bacterial type II fatty acid synthesis dehydrogenase FabX, has a bacteriostatic effect on Helicobacter pylori strains, and can be further made into an anti-Helicobacter pylori drug or used for treating or preventing diseases caused by Helicobacter pylori infection.

An inhalation preparation for treating pulmonary edema, comprising a pyridine sulfonamide phosphate compound represented by formula 1 or a pharmaceutically acceptable salt thereof and a cationic guar gum. The cationic guar gum can greatly improve the permeability of the pyridine sulfonamide phosphate compound or the pharmaceutically acceptable salt thereof in a Calu-3 cell model (an in vitro simulation of lung tissue epithelial cell model). The application also provides a preparation method of the inhalation preparation: under normal temperature and pressure, the main drug, the absorption promoter and the freeze-drying excipient are dissolved in water in proportion and are constant volume to the total amount, and are filtered and freeze-dried. The inhalation preparation prepared by the application has strong lung permeability, simple production process and good application prospect.